Background {#Sec1}
==========

Inflammatory myofibroblastic tumors (IMTs) are more frequent in children and young adults, and typically arise in the lung, abdominopelvic region, and retroperitoneum \[[@CR1], [@CR2]\]. Unusual sites of involvement include the head and neck, genitourinary tract, heart, extremities, and central nervous system \[[@CR2]\]. While these tumors are rare in the head and neck, they are even more uncommon in the mandible \[[@CR3]\].

IMTs are mesenchymal neoplasms of intermediate malignant potential and histologically characterized by the proliferation of fibroblasts and myofibroblasts admixed with lymphocytes, plasma cells, eosinophils, and histiocytes \[[@CR1]\]. The histological features of IMTs are often diagnostic, particularly through anaplastic lymphoma kinase (ALK) staining. The *ALK* gene has been implicated in the pathogenesis of IMTs, which supports the neoplastic origin of these tumors. Approximately 50% of IMTs harbor rearrangements in the *ALK* gene at 2p23 \[[@CR4]\]. However, to the best of our knowledge, an *ALK* fusion mutation has not yet been demonstrated in IMTs in the jawbone.

We herein report a case of an intraosseous IMT in the mandible including a novel *ATIC-ALK* fusion mutation.

Case presentation {#Sec2}
=================

Clinical features {#Sec3}
-----------------

An 11-year-old girl presented with the delayed eruption of tooth 43 (two digit tooth notation system of the FDI) and mental nerve palsy. She had no history of trauma. An intraoral examination revealed that tooth 43 had not erupted after the loss of tooth 83 and the gingiva and alveolar mucosa of the right mandible were normal. Panoramic tomography showed a unilocular radiolucent lesion in the right anterior mandible resorbing the root of tooth 42 and the medial side of the root of tooth 44 (Fig. [1a](#Fig1){ref-type="fig"}). Tooth 43 was not impacted in the mandibular bone. Computed tomography showed a well-circumscribed non-expansile 3-cm osteolytic lesion in the right anterior mandible that eroded the buccal cortical plate and resorbed the root of tooth 42 and the medial side of the root of tooth 44 (Fig. [1b](#Fig1){ref-type="fig"}). Root resorption and cortical plate erosion suggested a locally aggressive tumor. The tumor lesion was entirely curetted out. No recurrence was detected in 18 months of follow-up.Fig. 1**a** Panoramic tomography showed the resorption of the root of tooth 42 and medial side of the root of tooth 44 (*arrow heads*). **b** Computed tomography revealed a well- circumscribed 3-cm osteolytic lesion in the right mandible that eroded the buccal cortical plate and resorbed the roots of tooth 42 and tooth 44 (*arrows*)

Histopathological features and differential diagnosis {#Sec4}
-----------------------------------------------------

A histopathological investigation revealed plump spindle cell proliferation with a storiform architecture and lymphocytes scattered around the spindle cells (Fig. [2a](#Fig2){ref-type="fig"}, [b](#Fig2){ref-type="fig"}). The background stroma included a focal myxoid matrix. These spindle cells had ovoid nuclei with a pale eosinophilic cytoplasm, suggesting a myofibroblastic, myoepithelial, or fibroblastic lineage. Small islands of an odontogenic epithelium were detected. No mitosis or necrosis was observed. The histomorphological findings suggested that spindle cells were of a myofibroblastic, myoepithelial, or fibroblastic lineage. Small islands of an odontogenic epithelium suggested that this tumor was an odontogenic tumor. High-grade malignant tumors were excluded because neither mitosis nor necrosis was observed. Differential diagnoses included myofibroma, myoepithelioma, an odontogenic tumor, solitary fibrous tumor, giant cell granuloma, and IMT.Fig. 2Hematoxylin and eosin staining (**a**, **b**) and immunohistochemical staining (**c**, **d**). **a** The proliferation of plump spindle cells with a storiform architecture with scattered lymphocytes. Epithelioid components with an appearance suggestive of odontogenic epithelioid cells were detected. **b** Spindle cells contained ovoid nuclei with a pale eosinophilic cytoplasm. **c** Spindle cells were positive for SMA. **d** Spindle cells were positive for ALK

Immunohistochemical findings {#Sec5}
----------------------------

Immunohistochemical staining revealed that spindle cells were positive for α-smooth muscle actin (SMA) (Fig. [2c](#Fig2){ref-type="fig"}), ALK (Fig. [2d](#Fig2){ref-type="fig"}), CD10, and glial fibrillary acidic protein (GFAP), and negative for cytokeratin AE1/AE3, S100 proteins, and p63. The Ki67 labeling index was 3%.

Molecular pathological findings {#Sec6}
-------------------------------

### FISH {#Sec7}

A fluorescence *in situ* hybridization (FISH) *(ALK)* analysis was performed on a formalin-fixed paraffin-embedded (FFPE) tissue block. Rearrangements in the *ALK* gene at chromosome band 2p23 were detected by FISH utilizing a Vysis ALK break apart probe (Abott Molecular). The FISH analysis revealed the translocation of a part of the *ALK* gene locus (Fig. [3a](#Fig3){ref-type="fig"}).Fig. 3**a** FISH assay with a break apart probe for the *ALK* gene shows one intact yellow signal and one separated red and green signal per nucleus in tumor cells, indicating the presence of a rearrangement in the *ALK* gene. **b** The 5′ RACE analysis identified *ATIC* as a fusion partner. The sequence of the second round PCR product covering the fusion point (arrow) is shown. **c** The results of the RT-PCR analysis for *ATIC-ALK* are shown. PT: Present tumor, UT: Unrelated tumor (lung tumor), DW: Distilled Water, GAPDH: glyceraldehydes-3-phosphate dehydrogenase

### RACE {#Sec8}

Total RNA was extracted from frozen tissue using an RNeasy mini kit (Qiagen) according to the manufacturer's instructions. In order to obtain cDNA fragments corresponding to a novel *ALK* fusion gene, a rapid amplification of cDNA ends (RACE) analysis was performed using the 5′-full RACE core set (TaKaRa Bio) according to the manufacturer's instructions. First-strand cDNA synthesis was performed with a 5′ end-phosphorylated RT primer (5′-ATCTGGGCCTTGTATTTATCACTC). The primer set used for the first round of PCR was the A1 primer (5′-ACTTCCTGGTTGCTTTTGCTGGGGTAT) \[[@CR5]\] and S1 primer (5′-AGAAGGAGCCACACGACAGGGGTAA). The primer set used for the second round of PCR was the S2 primer (5′-CTCCTTCACAAACCAGAGACCAA) and A2 primer (5′-TTCAGGCAGCGTCTTCACAG). The second round PCR product covering the break point was sub-cloned into a pT7Blue plasmid vector (TaKaRa Bio). The DNA sequence was analyzed using universal primers (M13M4 primer or T7 promoter primer) and the Big-dye terminator ver3.1 kit (Applied Biosystems). A RACE analysis confirmed a rearrangement in ALK and identified ATIC (NM_004044) as a partner of this ALK fusion mutant (Fig. [3b](#Fig3){ref-type="fig"}).

### RT-PCR {#Sec9}

First-strand cDNA was synthesized from total RNA using the SuperScript First-Strand Synthesis System (Invitrogen) according to the manufacturer's instructions. RT-PCR was used to confirm the presence of the *AITC-ALK* fusion gene in this case. The primer set used was as follows: forward (5′-CCAAGCTTCCCATCACAGTGTACC) and reverse (5′-GAGGTCTTGCCAGCAAAGCAGTAG). RT-PCR was used to confirm the presence of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in this case. The primer set used was as follows: forward (5′-TGGAGTCCACTGGCGTCTTC) and reverse (5′-ATGACGAACATGGGGGCATCAG). A RT-PCR analysis confirmed the *ATIC-ALK* fusion in tumor cells (Fig. [3c](#Fig3){ref-type="fig"}).

Based on these results, the final diagnosis was IMT.

Discussion {#Sec10}
==========

We herein presented the first case of IMT with an *ATIC-ALK* fusion mutation primarily in the maxillofacial region. IMTs are rare mesenchymal tumors. Different terms have been applied to these lesions, namely, xanthogranuloma, plasma cell granuloma, inflammatory pseudotumor (IPT), and inflammatory myofibroblastic sarcoma \[[@CR1], [@CR6], [@CR7]\]. The diverse nomenclature is descriptive and reflects the uncertainty regarding the true biological nature of these lesions. In 2013, the World Health Organization classification of soft tissue and bone defined IMT as a distinctive neoplasm composed of myofibroblastic and fibroblastic spindle cells accompanied by an inflammatory infiltrate of plasma cells, lymphocytes, and/or eosinophils \[[@CR1]\]. The expression of ALK proteins is detected by anti-ALK immunohistochemistry in approximately 50% of IMT cases. ALK protein expression has been shown to reliably correlate with *ALK* gene rearrangements \[[@CR8]\]. These lines of evidence support ALK-positive IMT being a distinct neoplastic entity. ALK immunostaining is an aid in the pathological diagnosis of IMTs, as well as in the differentiation of IMTs from other spindle cell neoplasms that fall within the broad category of IPTs. We reviewed 12 cases of intraosseous tumors of the mandible with similar histological features in the literature (Table [1](#Tab1){ref-type="table"}) \[[@CR7], [@CR9]--[@CR19]\]. Six cases were diagnosed as IPTs and 6 as IMTs in the mandible. ALK-positive IMT/IPT in the mandible was initially reported in 2005 \[[@CR10]\] and only 4 cases including ours have been reported since then \[[@CR10], [@CR11], [@CR19]\].Table 1Clinicopathological features of IMTs in the mandible described in the present and previous reportsNo.Authors (yr.)Age (yr.)SexDiagnosisALK-IHCFISHRT-PCR1Zegarelli (1974) \[[@CR7]\]56FGranuloma (?IPT)NANANA2Inui (1993) \[[@CR9]\]63MIPTNANANA3Brooks (2005) \[[@CR10]\]82FIMTpositiveNANA4Poh (2005) \[[@CR11]\]42FIMTpositiveNANA5Oh (2008) \[[@CR12]\]20FIPTNANANA6Johann (2008) \[[@CR13]\]33MIPTNANANA7Satomi (2010) \[[@CR14]\]14FIMTnegativeNANA8Date (2010) \[[@CR15]\]70MIPTnegativeNANA9Sasagawa (2011) \[[@CR16]\]60MIMTNANANA10Gawande (2012) \[[@CR17]\]20MIPTNANANA11Sah (2013) \[[@CR18]\]30MIMTnegativeNANA12Stringer (2014) \[[@CR19]\]16MIMTpositiveNANA13Present case11FIMTpositivepositive*ATIC-ALKALK* anaplastic lymphoma kinase, IHC immunohistochemistry, FISH Fluorescene in situ hybridization, F female, M male, IPT Inflammatory pseudotumor, IMT Inflammatory myofibroblastic tumor, NA data not available

Thus, IMT may very rarely occur in the mandible. Otherwise, IMT may often be misdiagnosed because difficulties are associated with its histological differentiation from other spindle cell neoplasms and reactive lesions. Differential diagnoses include posttraumatic spindle cell nodules, giant cell granuloma, myofibroma, myoepithelioma, ameloblastic fibroma, odontogenic myxofibroma, IMT, a solitary fibrous tumor, low-grade myofibroblastic sarcoma, myofibrosarcoma, leiomyosarcoma, and spindle cell carcinoma. The immunohistochemical expression of the ALK protein is a very important hallmark for differentiating IMT from those described above. Therefore, if spindle cell lesions are detected in the jawbone, IMT must be included in the differential diagnosis and an immunohistochemical examination of ALK protein expression is needed.

The present tumor was confirmed to have the *ATIC-ALK* fusion mutation. Different *ALK* fusion partners, including *TPM3*, *TPM4*, *CLTC*, *CARS*, *RANBP2*, *ATIC*, *SEC31L1*, *PPFIBP1*, and *DCTN1*, in which *TPM3* is the most common partner, have been identified in IMTs \[[@CR5], [@CR20]--[@CR26]\]. *ATIC-ALK* fusion mutations are very rare, comprising approximately 1% of ALK-fusion mutations in anaplastic large cell lymphomas (ALCL) \[[@CR27]\]. The hypothetical schema of the gene fusion between *ATIC* and *ALK* is shown in Fig. [4](#Fig4){ref-type="fig"} \[[@CR28]\]. To the best of our knowledge, one case of urinary bladder IMT with the *ATIC-ALK* fusion mutation and one case of IMT arising from the hyoid bone in a neonate with the *ATIC-ALK* fusion have been reported in the literature \[[@CR23], [@CR29]\]. Thus, the present case is the first IMT with the *ATIC-ALK* fusion mutation primarily in the mandible.Fig. 4The hypothetical schema of the gene fusion between *ALK* and *ATIC. ATIC*-*ALK* fusion is generated by the pericentric inversion of chromosome 2 at the breakpoints of p23 and q35 \[inv(2)(p23q35)\], in which the *ALK* and *ATIC* genes are localized

The management of IMTs needs to entail complete surgical resection, including postoperative reassessments for at least 10 years \[[@CR30]\]. Although the number of IMTs in the jawbone is limited, they appear to exhibit a favorable clinical course. However, it is important to emphasize that IMTs occasionally behave in an aggressive manner. Poh et al. reported the local recurrence of an intraosseous mandibular IMT 14 months after initial surgery \[[@CR11]\]. Sasagawa et al. described a case of multiple IMTs involving the cranium, mandible, ischium, and calcaneus \[[@CR16]\]. The ALK inhibitor, crizotinib, was recently demonstrated to be clinically beneficial for IMTs with ALK fusion mutations \[[@CR26], [@CR31]--[@CR33]\].

Conclusion {#Sec11}
==========

IMTs are rare lesions in the mandible. The general consensus is that IMTs encompass a group of heterogeneous lesions with various biological behaviors. However, a proportion of cases are genuine neoplasms with the involvement of *ALK* fusion mutations. The recognition of this diagnostic entity is important for selecting appropriate treatments.

To the best of our knowledge, we are the first to describe IMT with the *ATIC-ALK* fusion mutation in the mandible.
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